Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:782401rdf:typepubmed:Citationlld:pubmed
pubmed-article:782401lifeskim:mentionsumls-concept:C1709854lld:lifeskim
pubmed-article:782401lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:782401lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:782401lifeskim:mentionsumls-concept:C0450127lld:lifeskim
pubmed-article:782401lifeskim:mentionsumls-concept:C0032952lld:lifeskim
pubmed-article:782401lifeskim:mentionsumls-concept:C0687742lld:lifeskim
pubmed-article:782401lifeskim:mentionsumls-concept:C0522536lld:lifeskim
pubmed-article:782401pubmed:issue8lld:pubmed
pubmed-article:782401pubmed:dateCreated1976-9-25lld:pubmed
pubmed-article:782401pubmed:abstractTextForty-five patients receiving renal allografts were gradually converted from daily to alternate-day prednisone therapy. Indications for conversion included aseptic necrosis, growth retardation in children and adolescents, obesity, diabetes, cataract formation, and cosmetic appearance. Eight of the 45 patients developed acute or chronic rejection during or just after completion of alternate-day steroid therapy. The remaining 37 patients had a notable decrease in the degree of hypercorticism, with return of growth in children and adolescents. However, there was no improvement once aseptic necrosis or cataract formation had occurred. Although the use of alternate-day prednisone therapy is of benefit in reducing the untoward side effects of corticosteroids, the risk of precipitating allograft rejection is a significant threat and must be carefully considered whenever this form of treatment is undertaken.lld:pubmed
pubmed-article:782401pubmed:languageenglld:pubmed
pubmed-article:782401pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:782401pubmed:citationSubsetAIMlld:pubmed
pubmed-article:782401pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:782401pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:782401pubmed:statusMEDLINElld:pubmed
pubmed-article:782401pubmed:monthAuglld:pubmed
pubmed-article:782401pubmed:issn0004-0010lld:pubmed
pubmed-article:782401pubmed:authorpubmed-author:DiethelmA GAGlld:pubmed
pubmed-article:782401pubmed:authorpubmed-author:SterlingW AWAlld:pubmed
pubmed-article:782401pubmed:authorpubmed-author:MorganJ MJMlld:pubmed
pubmed-article:782401pubmed:authorpubmed-author:HartleyM WMWlld:pubmed
pubmed-article:782401pubmed:issnTypePrintlld:pubmed
pubmed-article:782401pubmed:volume111lld:pubmed
pubmed-article:782401pubmed:ownerNLMlld:pubmed
pubmed-article:782401pubmed:authorsCompleteYlld:pubmed
pubmed-article:782401pubmed:pagination867-70lld:pubmed
pubmed-article:782401pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-H...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-A...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-H...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-C...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-C...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-O...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-C...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-K...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-G...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-C...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-F...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-F...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-M...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-A...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-D...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-P...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-M...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-T...lld:pubmed
pubmed-article:782401pubmed:meshHeadingpubmed-meshheading:782401-G...lld:pubmed
pubmed-article:782401pubmed:year1976lld:pubmed
pubmed-article:782401pubmed:articleTitleAlternate-day prednisone therapy in recipients of renal allografts. Risk and benefits.lld:pubmed
pubmed-article:782401pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:782401lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:782401lld:pubmed